Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics for rare hematological diseases, today announced that ARC1779 has received orphan drug designation from the European Commission (EC).

Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics for rare hematological diseases, today announced that ARC1779 has received orphan drug designation from the U.S. Food and Drug Administration.

Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics for rare hematological diseases, today announced that it started a Phase 2 clinical trial of ARC1779, which is designed to evaluate the safety and efficacy of ARC1779 as a first-in-class anti-platelet agent in patients suffering from a rare, life-threatening blood disorder known as thrombotic thrombocytopenic purpura, or TTP.

Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, announced today that it will receive a $1 million milestone payment from its collaborator Nuvelo, Inc.

Archemix Corp., a biotechnology company focused on